Insys Therapeutics Inc. announced Tuesday, July 5, that the United States Food and Drug Administration (FDA) has approved the company’s drug Syndros, an orally administered liquid formulation of the synthetic cannabinoid dronabinol, according to a release.
Christmas came early for cannabis research scientists. The U.S. Drug Enforcement Agency (DEA) decided to ease some of the regulatory requirements that had been imposed on those who were conducting FDA-approved clinical trials on cannabidiol (CBD).
GW Pharmaceuticals, which makes drugs derived from the cannabis plant, is scaling up its manufacturing capacity ahead of an expected approval of a new treatment for children with life-threatening epilepsy.
Copyright 2019 - 2024. WeedWorthy.com is a news division of MjLink.com, Inc.. All rights reserved. WeedWorthy
To contact the following departments, dial 1-844-420-4208 - Sales: Ext. #2 - Support: Ext. #3 - Investor Relations: Ext. #6
By using this website, you agree and understand that, by law: You MUST be at least 21 years of age to view any content on this website. To view the complete Terms of Use and Privacy Policy for this website, Click Here!
